Close Server: KOPWWW05 | Not logged in

Welcome to Health Care POV | sign in | join
ADVANCE Perspective: Respiratory Views

GSK’s Triple-COPD Trial a Success

Published June 20, 2016 12:28 PM by ADVANCE for Respiratory Care & Sleep Medicine

By Tamer Abouras


From Digital Look, some exciting — and relieving news — for GlaxoSmithKline.


European and U.S. regulatory submissions are likely to be completed the end of 2016 based on the data from this Phase III clinical test by GSK and its regular respiratory project partner, Innoviva.


The study showed the combination of three COPD medicines delivered meaningful improvements in lung function and health-related quality of life compared to the dual therapy of budesonide/formoterol.

SEE ALSO: Early Screening for COPD

Glaxo and Innoviva were testing their once-daily “closed” triple combination therapy of fluticasone furoate, an inhaled corticosteroid; umeclidinium, a long-acting muscarinic antagonist; and vilanterol, a long-acting beta agonist to treat patients with COPD in the 24-week “FULFIL” trial, standing for “lung FUnction and quality of LiFe assessment in COPD with closed trIpLe therapy.”


The study met its two co-primary endpoints, demonstrating statistically significant improvements compared with a twice-daily dose from a Symbicort Turbohaler in both lung function as measured by the “trough FEV1” measure of lung capability and health-related quality of life as measured by the St. George's Respiratory Questionnaire at the end of the study period.


Safety of the treatment was at the end of the trial and the 52-week extension was consistent with the individual medicines and their combinations, with the most common adverse events being nasopharyngitis, headache and COPD worsening.


ADVANCE Opinion Poll: What is the biggest reason for patient non-compliance with CPAP?


"Triple combination therapy is already a reality for many patients with COPD and is dispensed in multiple inhalers," said GSK's head of respiratory R&D, Dave Allen. "By combining three medicines in a single inhaler we can offer a convenient, once-daily dosing option to patients while improving their symptoms."


NYSE-listed Innoviva has partnered with GSK on combination respiratory products including Relvar/Breo, Ellipta and Anoro Ellipta.

You Might Also Like...

COPD Advantage

A new model for disease management settings.

Patient Handouts

COPD Exacerbations: Recognizing symptoms

Population Health and COPD

Patient education plays a critical role in improving quality of life.

Changes in COPD Treatment

Examining therapy options outside the hospital.


leave a comment

To prevent comment spam, please type the code you see below into the code field before submitting your comment. If you cannot read the numbers in the image, reload the page to generate a new one.

Enter the security code below:


About this Blog

Keep Me Updated